	US 11,866,499 B2
	Monospecific and multispecific anti-TMEFF2 antibodies and their uses
Philip Cooper, Philadelphia, PA (US); Robin Ernst, Kintnersville, PA (US); Rajkumar Ganesan, Blue Bell, PA (US); Colleen Kane, Flourtown, PA (US); Michael Russell, West Chester, PA (US); Sanjaya Singh, Blue Bell, PA (US); Sathyadevi Venkataramani, Blue Bell, PA (US); and Sheng-Jiun Wu, Broomall, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on May 21, 2019, as Appl. No. 16/417,889.
Claims priority of provisional application 62/675,957, filed on May 24, 2018.
Prior Publication US 2019/0359711 A1, Nov. 28, 2019
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)]

23 Claims

1. An isolated bispecific anti-TMEFF2/anti-CD3 antibody or an antigen binding fragment thereof comprising a first domain that binds TMEFF2 and a second domain that binds CD3, wherein the antibody binds to the membrane proximal region of SEQ ID NO: 110 of TMEFF2 and wherein

the first domain comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 of SEQ ID NOs: 10, 12, 15, 18, 20, and 86, respectively; and

the second domain comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 of SEQ ID NOs: 68, 69, 70, 71, 72, and 73, respectively.